Doxorubicin Market Research Report – Global Forecast till 2027

Doxorubicin Market: Information by Application (liver cancer, lung cancer), By Distribution Channel (hospital pharmacy, retail pharmacy) - Global Forecast Till 2027

ID: MRFR/MED/5907-HCR | February 2021 | Region: Global | 85 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario

The global doxorubicin market accounts for USD 916.5 million in 2017 and expected to register steady growth rate of 6.5% during the forecast period.

The market for doxorubicin is growing at steady pace. The various factors influencing the growth of the market include; increasing geriatric population and with-it growing prevalence of cancer cases and increasing awareness programs for cancer treatment are responsible for driving the growth of the market. In 2017, according to the Canadian Cancer Society it was estimated that around 206,200 new cases of cancer and 80,800 deaths were occurred in Canada due to cancer. Additionally, in 2016 according to the Office for National Statistics reported that over 303,135 cancers registered that is equal to 828 new cases were diagnosed each day during 2016.

The growing adoption for minimally invasive surgical procedures, large presence of surgical and ablation centers, and technological advancements are contributing to the rising demand for ablation technologies.

The cost suppression measures adopted by different governments, stringent regulatory authorities, and various side effects of doxorubicin are hampering the growth of the market during the forecast period.

Segmentation

The global doxorubicin market has been segmented on the basis of application, and distribution channel.

The application segment is divided into liver cancer, gastric cancer, breast cancer, bone sarcoma, prostate cancer, stomach cancer, ovarian cancer, leukemia and others.

The market, by distribution channel, has been segmented into hospital pharmacy, retail pharmacy and others.

The doxorubicin market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Doxorubicin market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European doxorubicin market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The doxorubicin market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The doxorubicin market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Global Doxorubicin Market Share, by Region, 2017 (%)

Doxorubicin Market

Source: MRFR Analysis

The Americas are expected to dominate the global doxorubicin market owing to the growing pool of cancer patients associated with increasing elderly population, strong presence of major manufacturers in the region, and adoption of advanced healthcare facilities coupled with increased awareness about cancer treatment in general population. In 2016, according to the National Cancer Institute in United states approximately USD 147.3 billion were spend for cancer care and around 15.5 million new cases of cancer were registered.

The European market is expected to be the second-largest doxorubicin market. The market growth in this region can be attributed to the growing prevalence of cancer along with rising healthcare expenditure is expected to drive the growth of the market. In 2016, according to European commission, the European nations invested 16.2% of its total expenditure on healthcare.

Asia-Pacific is expected to be the fastest-growing doxorubicin market during the forecast period owing to the continuously increasing investment in healthcare, increasing geriatric population in the region, and increasing opportunities for various manufacturers. According to the Economic and Social Commission for Asia and the Pacific (ESCAP), 12.4% of the total Asian population is 60 or above 60-year-old and by 2050 one third of the population will cross 60 year.

The market in the Middle East & Africa is expected to account for the smallest share of the global Doxorubicin market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Global Doxorubicin Market, by Application

Liver cancer

Gastric cancer

Breast cancer

Bone sarcoma

Prostate cancer

Stomach Cancer

Ovarian cancer

Leukemia

others

Global Doxorubicin Market, by Distribution Channel

Hospital pharmacy

Retail pharmacy

Others

Global Doxorubicin Market, by Region

Americas
- North America
  - US
  - Canada
- South America

Europe
- Western Europe
  - Germany
  - France
  - Italy
  - Spain
  - UK
  - Rest of Western Europe
- Eastern Europe

Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

The Middle East & Africa
- Middle East
- Africa

Company Profiles

Pfizer, Inc

Sun Pharmaceutical Industries Ltd.

Janssen Pharmaceuticals

Accord Healthcare

Novartis AG

Sandoz

Reddy’s Laboratories Ltd.

Teva Pharmaceuticals

GLENMARK PHARMACEUTICALS LTD.

Intended Audience

Doxorubicin manufacturing suppliers and companies

Healthcare providers

Research institutes and academic centers

Contract manufacturing organizations (CMOs)

Market research and consulting

Frequently Asked Questions (FAQ) :

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Doxorubicin Market, by Application

6.1 Introduction

6.2 Liver cancer

Market Estimates & Forecast, by Region, 2020-2027